Cargando…

Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study

BACKGROUND: Pirfenidone and nintedanib are the sole pharmacological therapies currently approved for idiopathic pulmonary fibrosis (IPF). Limited comparison data is available in literature, despite they are both prescribed for mild-to-moderate disease. Here, we describe our almost 10 years real-life...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cameli, Paolo, Refini, Rosa Metella, Bergantini, Laura, d’Alessandro, Miriana, Alonzi, Valerio, Magnoni, Carlo, Rottoli, Paola, Sestini, Piersante, Bargagli, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Molecular Biosciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498677/ https://www.ncbi.nlm.nih.gov/pubmed/33102528 http://dx.doi.org/10.3389/fmolb.2020.581828

Ejemplares similares

The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study
por: Cameli, Paolo, et al.
Publicado: (2022)

Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena
por: Vietri, Lucia, et al.
Publicado: (2020)

The role of the combination of echo-HRCT score as a tool to evaluate the presence of pulmonary hypertension in idiopathic pulmonary fibrosis
por: Refini, Rosa Metella, et al.
Publicado: (2020)

Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy
por: d’Alessandro, Miriana, et al.
Publicado: (2021)

Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy
por: Landi, Claudia, et al.
Publicado: (2020)

Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis
por: Bargagli, Elena, et al.
Publicado: (2020)

Adaptive immune system in pulmonary sarcoidosis—Comparison of peripheral and alveolar biomarkers
por: d’Alessandro, Miriana, et al.
Publicado: (2021)

Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review
por: Cameli, Paolo, et al.
Publicado: (2020)

Systematic Review and Metanalysis of Oncomarkers in IPF Patients and Serial Changes of Oncomarkers in a Prospective Italian Real-Life Case Series
por: d’Alessandro, Miriana, et al.
Publicado: (2021)

Hypercalciuria in Sarcoidosis: A Specific Biomarker With Clinical Utility
por: Cameli, Paolo, et al.
Publicado: (2020)

Correction to: Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis
por: Bennett, David, et al.
Publicado: (2020)

Common Molecular Pathways Between Post-COVID19 Syndrome and Lung Fibrosis: A Scoping Review
por: Bergantini, Laura, et al.
Publicado: (2022)

Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis
por: Bennett, David, et al.
Publicado: (2020)

Prognostic Significance of Obstructive Sleep Apnea in a Population of Subjects with Interstitial Lung Diseases
por: Valecchi, Debora, et al.
Publicado: (2023)

Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy
por: Bergantini, Laura, et al.
Publicado: (2021)

Alveolar Nitric Oxide as a Biomarker of COVID-19 Lung Sequelae: A Pivotal Study
por: Cameli, Paolo, et al.
Publicado: (2021)

NK and T Cell Immunological Signatures in Hospitalized Patients with COVID-19
por: Bergantini, Laura, et al.
Publicado: (2021)

Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6
por: Bergantini, Laura, et al.
Publicado: (2019)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Utility of serological biomarker’ panels for diagnostic accuracy of interstitial lung diseases
por: Bergantini, Laura, et al.
Publicado: (2020)

Exploring the Interaction between Fractional Exhaled Nitric Oxide and Biologic Treatment in Severe Asthma: A Systematic Review
por: Pianigiani, Tommaso, et al.
Publicado: (2023)

Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis
por: Lehtonen, Siri T., et al.
Publicado: (2016)

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
por: Belhassen, Manon, et al.
Publicado: (2021)

Clinical phenotyping in sarcoidosis management
por: Rana, Giuseppe Domenico, et al.
Publicado: (2021)

Serum Amyloid A in lung transplantation
por: Vietri, Lucia, et al.
Publicado: (2020)

The Role of Galectins in Chronic Lung Allograft Dysfunction
por: d’Alessandro, Miriana, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
por: Rinciog, C., et al.
Publicado: (2020)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis With Pirfenidone and Nintedanib: A Friend or Foe
por: Kaushal, Mohit, et al.
Publicado: (2022)

Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
por: Takehara, Kazutaka, et al.
Publicado: (2022)

Oxygen Therapy during Exercise in Patients with Interstitial Lung Diseases
por: Viani, Magda, et al.
Publicado: (2022)

Cytomegalovirus Infection Is Associated with Development of Chronic Lung Allograft Dysfunction
por: Bennett, David, et al.
Publicado: (2022)

Regulatory and Effector Cell Disequilibrium in Patients with Acute Cellular Rejection and Chronic Lung Allograft Dysfunction after Lung Transplantation: Comparison of Peripheral and Alveolar Distribution
por: Bergantini, Laura, et al.
Publicado: (2021)

Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study
por: Marijic, Pavo, et al.
Publicado: (2021)

High-dose steroids for the treatment of severe COVID-19: a new therapeutic tool?
por: Cameli, Paolo, et al.
Publicado: (2021)

Combined Sarcoidosis and Idiopathic Pulmonary Fibrosis (CSIPF): A New Phenotype or a Fortuitous Overlap? Scoping Review and Case Series
por: Bergantini, Laura, et al.
Publicado: (2022)

Pharmacological treatment of idiopathic pulmonary fibrosis – preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine
por: Myllärniemi, Marjukka, et al.
Publicado: (2015)

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis
por: Hughes, Gareth, et al.
Publicado: (2016)

Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study
por: Moor, C. C., et al.
Publicado: (2020)

Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
por: Serra López-Matencio, José M., et al.
Publicado: (2021)

Bronchoalveolar-Lavage-Derived Fibroblast Cell Line (B-LSDM7) as a New Protocol for Investigating the Mechanisms of Idiopathic Pulmonary Fibrosis
por: Bergantini, Laura, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o8t3nseruirldd0qe3u8tujc2s